[Comparison of current clinical practice and guideline application in therapies of ACS: findings from the Multi-central Collaborative Group on Chinese registry of acute coronary events].
To evaluate the current practice of medications that have been proven effective by evidence-based medicine on patients with ACS. (One thousand three hundred and one patients with ACS from 12 hospitals in China received different therapies in hospitals. We analyzed the status of application of reperfusion and aspirin, ACEI, beta-blocker, LWMH and cholesterol lowering agents on different ACS patients. (1) Percentage of medications in STEMI patients in different periods: aspirin (95.9%-100.0%), ACEI (72.0%-88.4%), beta-blocker (62.7%-74.5%), LWMH (84.7%-100.0%), cholesterol lowering agents (72.5%-93.0%); (2) In NSTEMI patients: aspirin (100%), LWMH in NSTEMI patients (84.2%-100.0%), in UAP patients (65.1%-87.2%); (3) Among STEMI patients, 48.9% received primary PCI, 12% received Fibrinolytics only, and nearly 28.8% did not receive any form of reperfusion. (4) 50% of NSTEACS patients received PCI therapy. We conclude that in the developed regions in China the application of medications being proved effective by evidence-based medicine in clinical practice is better than that reported in other countries, and that the application status in China could be further improved.